These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8724413)

  • 21. Comparison of Contrast-Enhanced Ultrasound and Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI for the Diagnosis of Macroscopic Type of Hepatocellular Carcinoma.
    Iwamoto T; Imai Y; Kogita S; Igura T; Sawai Y; Fukuda K; Yamaguchi Y; Matsumoto Y; Nakahara M; Morimoto O; Seki Y; Ohashi H; Fujita N; Kudo M; Takehara T
    Dig Dis; 2016; 34(6):679-686. PubMed ID: 27750237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence.
    Reimer P; Rummeny EJ; Shamsi K; Balzer T; Daldrup HE; Tombach B; Hesse T; Berns T; Peters PE
    Radiology; 1996 Apr; 199(1):177-83. PubMed ID: 8633143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging.
    Reimer P; Rummeny EJ; Daldrup HE; Hesse T; Balzer T; Tombach B; Peters PE
    Eur Radiol; 1997; 7(2):275-80. PubMed ID: 9038130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usefulness of combination of imaging modalities in the diagnosis of hepatocellular carcinoma using Sonazoid®-enhanced ultrasound, gadolinium diethylene-triamine-pentaacetic acid-enhanced magnetic resonance imaging, and contrast-enhanced computed tomography.
    Alaboudy A; Inoue T; Hatanaka K; Chung H; Hyodo T; Kumano S; Murakami T; Moustafa EF; Kudo M
    Oncology; 2011; 81 Suppl 1():66-72. PubMed ID: 22212939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection and characterization of primary liver cancer in rats by MS-264-enhanced MRI.
    Petré C; Ni Y; Marchal G; Yu J; Wevers M; Lauffer RB; Baert AL
    Magn Reson Med; 1996 Apr; 35(4):532-9. PubMed ID: 8992203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
    Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
    Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamic-contrast-enhanced magnetic resonance imaging of cirrhotic liver parenchyma: A comparison between gadolinium-diethylenetriamine pentaacetic acid and gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid.
    Lin CY; Chang WC; Chou CT; Chen RC
    J Chin Med Assoc; 2015 Nov; 78(11):666-72. PubMed ID: 26341453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of radiation-induced liver injury with MR imaging: comparison of hepatocellular and reticuloendothelial contrast agents.
    Clément O; Mühler A; Vexler VS; Rosenau W; Berthezène Y; Kuwatsuru R; Brasch RC
    Radiology; 1992 Oct; 185(1):163-8. PubMed ID: 1523301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow.
    Kogita S; Imai Y; Okada M; Kim T; Onishi H; Takamura M; Fukuda K; Igura T; Sawai Y; Morimoto O; Hori M; Nagano H; Wakasa K; Hayashi N; Murakami T
    Eur Radiol; 2010 Oct; 20(10):2405-13. PubMed ID: 20490505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatobiliary enhancement with Gd-EOB-DTPA: comparison of spin-echo and STIR imaging for detection of experimental liver metastases.
    Mühler A; Clément O; Vexler V; Berthezène Y; Rosenau W; Brasch RC
    Radiology; 1992 Jul; 184(1):207-13. PubMed ID: 1609081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.
    Clément O; Mühler A; Vexler V; Berthezène Y; Brasch RC
    Invest Radiol; 1992 Aug; 27(8):612-9. PubMed ID: 1428739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma.
    Narita M; Hatano E; Arizono S; Miyagawa-Hayashino A; Isoda H; Kitamura K; Taura K; Yasuchika K; Nitta T; Ikai I; Uemoto S
    J Gastroenterol; 2009; 44(7):793-8. PubMed ID: 19404564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gd-EOB-DTPA-enhanced-MR imaging in the inflammation stage of nonalcoholic steatohepatitis (NASH) in mice.
    Yamada T; Obata A; Kashiwagi Y; Rokugawa T; Matsushima S; Hamada T; Watabe H; Abe K
    Magn Reson Imaging; 2016 Jul; 34(6):724-729. PubMed ID: 26979540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experimental hepatic dysfunction: evaluation by MRI with Gd-EOB-DTPA.
    Kim T; Murakami T; Hasuike Y; Gotoh M; Kato N; Takahashi M; Miyazawa T; Narumi Y; Monden M; Nakamura H
    J Magn Reson Imaging; 1997; 7(4):683-8. PubMed ID: 9243389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different signal intensity at Gd-EOB-DTPA compared with Gd-DTPA-enhanced MRI in hepatocellular carcinoma transgenic mouse model in delayed phase hepatobiliary imaging.
    Korkusuz H; Knau LL; Kromen W; Bihrer V; Keese D; Piiper A; Vogl TJ
    J Magn Reson Imaging; 2012 Jun; 35(6):1397-402. PubMed ID: 22267126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging.
    Hamm B; Staks T; Mühler A; Bollow M; Taupitz M; Frenzel T; Wolf KJ; Weinmann HJ; Lange L
    Radiology; 1995 Jun; 195(3):785-92. PubMed ID: 7754011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatic kinetics and magnetic resonance imaging of gadolinium-EOB-DTPA in dogs.
    Benness G; Khangure M; Morris I; Warwick A; Burrows P; Vogler H; Weinmann HJ
    Invest Radiol; 1996 Apr; 31(4):211-7. PubMed ID: 8721960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison between areas with Gd-EOB-DTPA uptake and without in hepatocellular carcinomas on Gd-EOB-DTPA-enhanced hepatobiliary-phase MR imaging: pathological correlation.
    Lee S; Kim SH; Park CK; Kim YS; Lee WJ; Lim HK
    J Magn Reson Imaging; 2010 Sep; 32(3):719-25. PubMed ID: 20815073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI).
    Motosugi U; Ichikawa T; Sou H; Sano K; Ichikawa S; Tominaga L; Araki T
    J Magn Reson Imaging; 2009 Oct; 30(4):849-54. PubMed ID: 19787734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatic kinetics and magnetic resonance imaging of gadolinium ethoxybenzyl diethylenetriaminepentacetic acid (Gd-EOB-DTPA) in dogs.
    Benness G; Khangure M; Morris I; Warwick A; Burrows P
    Australas Radiol; 1993 Aug; 37(3):252-5. PubMed ID: 8373327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.